ABSTRACT
AIMS: Assess the efficacy and safety of saxagliptin added to a submaximal sulphonylurea dose vs. uptitration of sulphonylurea monotherapy in patients with type 2 diabetes and inadequate glycaemic control with sulphonylurea monotherapy. METHODS AND PATIENTS: A total of 768 patients (18-77 years; HbA(1c) screening >or= 7.5 to Subject(s)
Adamantane/analogs & derivatives
, Blood Glucose/drug effects
, Diabetes Mellitus, Type 2/drug therapy
, Dipeptides/therapeutic use
, Hypoglycemic Agents/therapeutic use
, Sulfonylurea Compounds/therapeutic use
, Adamantane/therapeutic use
, Adolescent
, Adult
, Aged
, Analysis of Variance
, Double-Blind Method
, Drug Therapy, Combination
, Humans
, Middle Aged
, Treatment Outcome
, Young Adult
ABSTRACT
The aim of this study was to determine the prevalence of HTLV-1 seropositivity in those blood donors, food handlers and patients with symptoms suggestive of HTLV-1 infection who were seen at the Georgetown Hospital from July 15 to September 30, 1992. Sera were tested for HTLV-1 antibodies at the Caribbean Epidemiology Centre. Three hundred and fifty-four subjects were studied of whom 279 (79 per cent) were blood donors and 75 (21 per cent) food handlers; 3.9 per cent of the former (11/279) and 12.0 per cent of the latter (9/75) were seropositive with an overall seropositivity of 5.6 per cent. Although Indo-Guyanese accounted for about 40 per cent of the total sample there was only one Indo-Guyanese who was seropositive for HTLV-1. The presence of signs and symptoms associated with HTLV-1 infection was not a useful predictor of the disease (AU)